Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trivalent antivenom
- Development stage
- Phase 2
- Lead developer
- Instituto Butantan
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Freeze-dried trivalent antivenom (FDTAV) is a lyophilized biological preparation developed for the treatment of snakebite envenoming caused by the three most medically significant snake genera in the Brazilian Amazon: *Bothrops* (jararaca), *Lachesis* (bushmaster), and *Crotalus* (rattlesnake). Developed by the Army Institute of Biology (Instituto de Biologia do Exército) in collaboration with the Butantan Institute, FDTAV consists of purified F(ab')2 fragments of immunoglobulins raised in horses against these specific venoms. The primary innovation of this formulation is its freeze-dried state, which allows for storage and transport without a strict cold chain, facilitating distribution to remote tropical regions where refrigeration is unavailable. It has been evaluated in Phase II clinical trials in Brazil to compare its safety and efficacy against standard liquid antivenoms.
- Other names
- freeze-dried trivalent antivenomsoro antiofídico polivalente liofilizado
02
Targets
BVT (Bothrops venom toxins)Crotalus durissus terrificus venom toxinsLachesis muta venom toxinsLachesis venom toxins
Beyond the preview
Go deeper on trivalent antivenom.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trivalent antivenom.